Navigation Links
Covance and the Indiana CTSI to collaborate on early clinical research
Date:9/4/2013

PRINCETON, N.J., and INDIANAPOLIS -- Covance Inc. (NYSE: CVD), a leading global drug development services company, and the Indiana Clinical and Translational Sciences Institute, part of the Indiana University School of Medicine, today announced an agreement to collaborate in conducting early clinical trials for new medicines on behalf of biotechnology and pharmaceutical companies.

This alliance provides a significant opportunity to bring more Phase I clinical research to Indiana, through the clinical research unit located within the IU School of Medicine in Indianapolis and Covance's clinical research unit located in Evansville. Phase I clinical research includes studies where investigational new drugs are administered to humans for the first time.

Working together, the two organizations will conduct high-quality research in a safe and regulated environment for sponsors who are looking to recruit both healthy volunteers and patients for early clinical studies.

"The alliance with the Indiana CTSI will help us provide biopharmaceutical clients with quicker access to patients in a hospital setting that supports specialized care and monitoring," said Rob Aspbury, vice president and general manager, Global Clinical Pharmacology Services at Covance. "With quicker access to patients, we can streamline the drug development process and bring important new medications to patients who need them."

The Indiana CTSI will provide access to a 13,606-square-foot, 24-patient facility at IU Health University Hospital in Indianapolis. The institute also stands ready to expand operations into a recently renovated 33,078-square-foot, 50-patient facility in the same building. This space re-opens to clinical research for the first time in six years due to the efforts of the Indiana CTSI.

"The Indiana CTSI works every day to support tremendously talented biomedical scientists whose discoveries have the potential to translate into life-saving new therapies and treatments," said Anantha Shekhar, M.D., Ph.D., director of the Indiana CTSI, associate dean for translational research, and the Raymond E. Houk Professor of Psychiatry at the IU School of Medicine. "Our mission is to accelerate the rate at which this research travels out of the lab and into the care of the patients who need it. This alliance with Covance will greatly enhance our ability to accomplish this vital work."

Services provided by the Indiana CTSI include access to 24-hour nursing support, in-patient and out-patient facilities, on-site laboratory analyses and professional patient recruitment services. These patient recruitment efforts are strengthened through robust patient data from the Regenstrief Institute, a partner of the Indiana CTSI which houses the Indiana Network for Patient Care, in which more than 70 Indiana hospitals share nearly 80 percent of the state's electronic medical record data. Additional patient and support services are provided through its affiliation with IU Health.

The alliance between Covance and the Indiana CTSI was facilitated by BioCrossroads, an organization that advances Indiana's signature strengths in the life sciences by connecting corporations, academic institutions and philanthropic organizations.

"This is a major milestone for both Covance and the Indiana CTSI. It's the type of public-private partnership that really can influence breakthroughs in medicine," said Deborah Keller, executive vice president and group president, R&D Laboratories at Covance, and a member of the BioCrossroads Board of Directors. "Indiana is unique in its depth and breadth of drug development opportunities, both on the corporate and academic sides, and this collaboration is a shining example of bringing the two together thanks to the work and support of BioCrossroads."

Covance has been conducting Phase I clinical trials for more than 35 years. In addition to its 80-bed clinical research unit in Evansville, Ind., Covance has clinics in Madison, Wis.; Daytona, Beach, Fla.; Dallas, Texas; and Leeds, UK. In 2012, Covance conducted more than 100 Phase I trials globally. Covance also has a similar Phase I clinical research alliance with the Royal Liverpool University Hospital in Liverpool, UK.


'/>"/>

Contact: Kevin Fryling
kfryling@iu.edu
317-278-0088
Indiana University
Source:Eurekalert

Related medicine news :

1. Indiana’s Largest Optical Retailer Forges Exclusive Partnership with Rising Philanthropic Eyewear Brand
2. Viewpoints Industry TV Welcomes Evansville, Indiana to Its Viewing Area
3. New Report: Statewide Smokefree Law Would Not Hurt Indiana Restaurant, Bar Businesses
4. New Incline Platform Wheelchair Lift from Butler Mobility is Carried by Access Elevator Serving Southern Wisconsin, Northern Illinois and Northwest Indiana
5. Indianapolis Colts Renew 20/20 Institute as Official LASIK Provider
6. Blake Shelton Tickets: Cheap Concert Tickets Slashes Ticket Prices in Long Island, Virginia Beach, Indianapolis, DC, St. Louis, Cincinnati, Pittsburgh, Chicago & Camden
7. Superior Van & Mobility Announces Participation in the "My Finish Line" Movie and Music Tour at their Evansville, Indiana location July 30th from 2 to 5 p.m.
8. Elevate Ventures Partners with Southwest Indiana Region Community Stakeholders to Launch Regional Entrepreneurship Action Plan
9. Certified ScrumMaster Training Weekend Edition August 24-25 in Indianapolis Presented by BeardedEagle
10. The Eagles Tickets in Lincoln, Denver, Tulsa, Wichita, Dallas, Memphis, Nashville, Indianapolis, Chicago Rosemont, Moline, Kansas City & St. Louis Presales Begin 6/7/13
11. Seva Call Launches in Flood Hit Fort Wayne, Indiana
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... Florida Hospital presents Heart ... on the St. Louis Blues at the Amalie Arena. The puck drops at 6:00pm, ... heart exhibit, the MEGA Heart, prior to the game. The MEGA Heart will be ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... ranked among the top five firms in the “2015/2016 Best in KLAS: Software ... and Staffing. KLAS is a research and insights firm on a global mission ...
(Date:2/11/2016)... ... February 11, 2016 , ... In a ... Dallas plastic surgeon , Dr. Rod J. Rohrich, and colleagues, examine and underscore ... outlines recommendations for rhinoplasty surgeons when addressing this vital area. , The upper ...
(Date:2/11/2016)... ... February 11, 2016 , ... "What holds you ... Ray Clarke poses a question as a challenge for his readers to examine ... in the Being" (published by Partridge Singapore), Clarke explores the subject with more ...
(Date:2/11/2016)... , ... February 11, 2016 , ... Colorado spine surgeon, ... one of 334 spine surgeons to know in 2016 . The list consists ... field of spine surgery. , Dr. Corenman understands the importance of clinical excellence; ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... and PORTLAND, Ore. , Feb. ... optimization company, is pleased to announce the acquisition of ... community and rural access hospitals. Along with providing traditional ... 340B consulting services to assist clients in navigating the ... Love , CEO of Wellpartner. --> James ...
(Date:2/11/2016)... DUBLIN, February 11, 2016 Transformational M&A ... with Baxalta   --> Transformational M&A achieved through ...   --> Transformational M&A achieved through NPS ... Positioned for future growth with most robust pipeline ... Positioned for future growth with most robust pipeline in ...
(Date:2/11/2016)... , February 11, 2016 ... release of a new research report, titled "Sports Medicine Devices ... Forecast, 2013 - 2019". According to the report, the global ... 4.40% CAGR from 2013 to 2019, growing from a value ... --> --> The global ...
Breaking Medicine Technology: